LEO Pharma

LEO Pharma Enters License Agreement with Oneness Biotech and Microbio Shanghai for FB825 a Novel Atopic Dermatitis and Asthma Drug Candidate

Share

BALLERUP, Denmark, April 15, 2020 – LEO Pharma A/S, a global leader in medical dermatology, today announced that is has signed a worldwide exclusive licensing agreement with Oneness Biotech (Taiwan, TPEx: 4743) and Microbio Shanghai (China) covering the development and commercialization of the novel Atopic Dermatitis (AD) and Allergic Asthma drug candidate, FB825.

FB825 is a first-in-class drug candidate with a unique mechanism of action (MoA) targeting the CεmX domain of the membrane bound IgE (mIgE) causing a depletion of mIgE positive B-cells. This new MoA holds promise as a treatment for atopic dermatitis and is expected to reduce the disease burden by lowering relevant inflammatory mediators as well as IgE levels.

“Having seen the first-in-human data of FB825 and the reduction in Eczema Area and
Severity Index scores (an indicator of AD severity), we feel that we are welcoming a
promising novel drug candidate into our development pipeline,” said Dr Kim Kjoeller,
Executive Vice President, Global Research & Development, LEO Pharma. “No two
patients are alike, and as there is a high unmet need we are committed to building a
diverse pipeline that represents a broad range of molecules and mechanisms of action”.

LEO Pharma and both Oneness Biotech and Microbio Shanghai see great potential in
FB825. If the anticipated treatment profile can be confirmed in the upcoming trials, the
product can be expected to help a significant number of patients suffering from atopic
diseases.

Under the terms of the agreement, LEO Pharma will make an upfront payment of
USD 40 million and offer milestone payments up to USD 530 million, followed by a tiered
high single-digit to double-digit royalties. Under the agreement, Oneness will be
responsible for executing the Phase 2a study for Atopic Dermatitis in the United States
and Microbio Shanghai will execute the Phase 2a study for allergic asthma in China. LEO
Pharma will assume all the development responsibilities after the Phase 2a studies.

#END#

NOTES TO EDITORS

About FB825

FB825 is a humanized monoclonal antibody that binds to the CεmX domain of membrane
form IgE, leading to depletion of IgE+ B lymphocytes by inducing apoptosis and antibodydependent cellular cytotoxicity (ADCC). FB825 is scheduled to be tested in Phase 2 trials for Atopic Dermatitis in US and for Allergic Asthma in China. In addition, FB825 is granted an orphan drug designation by US FDA in Hyper IgE Syndrom (HIES).
About Atopic Dermatitis Atopic dermatitis (AD) – also known as ‘atopic eczema’ – is a chronic, inflammatory, heterogeneous skin disease characterized by intense itch and eczematous lesions.(2) AD is the most common inflammatory skin disease in the developed world,(3) affecting up to 5% of adults across the US, Canada, Europe and Japan.(4, 5)

About Asthma

Allergic Asthma, which is the most common form of asthma triggered by inhaling
allergens. The severe form of asthma affecting an estimated 300 million(1)
individuals worldwide, is a debilitating, potentially fatal disease that has a significant negative impact on patients’ lives, often leading to frequent, severe attacks, reduced lung function and a poor quality of life.

About Oneness Biotech

Oneness Biotech, a listed biotech company in Taiwan (TPEx: 4743), is dedicated to fulfilling the unmet needs in diabetes-related and immune diseases. Besides FB825, Oneness Biotech has another new drug, ON101 in diabetic foot ulcer that completed recruitment of its first global Phase 3 trial. According to its interim analysis, ON101 has achieved over 60% complete healing rate within 16 weeks (p=0.0065). In the past 20 years, all Phase 3 clinical trials in DFU have failed. In addition, Oneness Biotech’s pipeline further includes fully-human antibody anti-IL 6, anti-IL 33 and other new drugs under development. For more information, please visit: www.onenessbio.com.tw/en

About Microbio Shanghai

Microbio Shanghai (“MBS”) is a company focused on immune and metabolic diseases. MBS will conduct Phase 2 trial of FB825 in allergic asthma in China. In addition, MBS is specialized in research and development into nucleic acid medicines and microbiome via its unique microbial pharmaceutical technology platforms. Its library with hundreds of unique anaerobic commensal bacteria metabolites has obtained significant findings in treatment of diabetes and immune diseases which takes it a further step into nextgeneration medicines.

References

1. Msaoli et. al., Allergy 2004.
2. Weidinger S & Novak N. Atopic dermatitis. Lancet 2016;387:1109-1122.
3. Weidinger S et al. Atopic Dermatitis. Nat Rev Dis Primers 2018; 4(1):1.
4. Barbarot S, Auziere S et al. Epidemiology of atopic dermatitis in adults: Results from an international survey. Allergy. 2018;73(6):1284-1293. doi: 10.1111/all.13401.
5. Barbarot S et al. Epidemiology of atopic dermatitis in adults: Results from an international survey. Allergy 2018;73:1284-1293.

Contacts

LEO Pharma A/S
Maia Fredtoft Søchting,
Corporate Communications Manager
+45 2681 4579
mfddk@leo-pharma.com

About LEO Pharma

LEO Pharma
LEO Pharma
Industriparken 55
2750 Ballerup

4494 5888http://www.leo-pharma.com/

LEO Pharma helps people achieve healthy skin. The company is a leader in medical  dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 92 million patients in 130 countries. In 2019, the company generated net sales of DKK 10,805 million. For more information please visit: www.leo-pharma.com

Subscribe to releases from LEO Pharma

Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from LEO Pharma

LEO Pharma presents results from study of twice-weekly Enstilar® (calcipotriene and betamethasone dipropionate) Foam for topical use in long-term maintenance treatment of plaque psoriasis12.6.2020 21:20:42 CESTPress release

New results from the PSO-LONG clinical trial are the first to provide long-term maintenance data for plaque psoriasis with a twice-weekly topical treatment with Enstilar®(calcipotriene and betamethasone dipropionate) Foam Plaque psoriasis is a chronic, multifactorial disease affecting nearly 80% of the 125 million people living with psoriasis worldwide(1,2) LEO Pharma is committed to building on its more than 30-year heritage of pursuing innovative products for patients affected by psoriasis and other chronic skin conditions BALLERUP, Denmark, JUNE 12, 2020 – LEO Pharma A/S, a global leader in medical dermatology, today presented results from the Phase 3 PSO-LONG clinical trial. PSO-LONG compared the efficacy and safety of twice-weekly Enstilar® (calcipotriene and betamethasone dipropionate)Foam, versus foam vehicle for long-term (52-week) maintenance treatment for adult patients with plaque psoriasis.(3,4) Results were presented as ePosters online at the American Academy of Dermatolog

Tralokinumab achieves primary and secondary endpoints in three pivotal Phase 3 trials in adult patients with moderate-to-severe atopic dermatitis12.6.2020 21:06:15 CESTPress release

Presented at the AAD VMX 2020, results from ECZTRA 1, 2 and 3 trials confirm tralokinumab met its primary and secondary endpoints and are the first Phase 3 results in atopic dermatitis for an investigational therapy that specifically targets IL-13 Tralokinumab demonstrated statistically significant improvements in outcomes including pruritus (itch) and health-related quality of life measures that are important to patients In ECZTRA 1 and 2, the majority of patients treated with tralokinumab 300 mg every two weeks who achieved a clinical response at week 16, maintained response at week 52 without any use of topical corticosteroids In ECZTRA 3, nine out of 10 patients who achieved clear or almost clear skin with tralokinumab 300 mg in combination with topical corticosteroids at week 16 maintained this response at week 32 when randomized to dosing every two weeks. Similarly, eight out of 10 patients randomized to dosing every four weeks at week 16 maintained clear or almost clear skin at

LEO Pharma announces European Medicines Agency acceptance of marketing authorization application for tralokinumab for the treatment of adults with moderate-to-severe atopic dermatitis11.6.2020 14:00:00 CESTPress release

BALLERUP, Denmark, JUNE 11, 2020 – LEO Pharma A/S, a global leader in medical dermatology, today announced that the European Medicines Agency (EMA) validated the marketing authorization application (MAA) for tralokinumab, an investigational product for the treatment of adult patients with moderate-to-severe atopic dermatitis (AD). The acceptance of this MAA marks the beginning of the formal review procedure for this potential new treatment by the EMA’s Committee for Medicinal Products for Human Use (CHMP).

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom